However, it is considered an inflammatory disease with hypergammaglobulinemia (35–46%), adequate response to steroids (in 97% of patients with monotherapy), slight antinuclear antibody (ANA) positivity (5.7–17%), and eosinophilia in peripheral blood (58–85%) [35], which is often present during the acute phase with reduced levels posttreatment; however, the latter is not a major criterion for the diagnosis [32, 33]. The gene discussed is BTG3; the disease is Increased total eosinophil count.